BIAF vs XTLB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.
XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.
Compare Another Pair
Related Comparisons
BIAF vs XTLB: Head-to-Head Comparison
This page compares bioAffinity Technologies, Inc. (BIAF) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.